Daily Stock Analysis, CLSD, Clearside Biomedical Inc, priceseries

Clearside Biomedical Inc. Daily Stock Analysis
Stock Information
Open
1.05
Close
1.03
High
1.06
Low
1.02
Previous Close
1.04
Daily Price Gain
-0.01
YTD High
1.90
YTD High Date
Feb 20, 2019
YTD Low
0.95
YTD Low Date
Jun 12, 2019
YTD Price Change
-0.12
YTD Gain
-10.43%
52 Week High
11.24
52 Week High Date
Jul 6, 2018
52 Week Low
0.95
52 Week Low Date
Jun 12, 2019
52 Week Price Change
-9.56
52 Week Gain
-90.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
8.06
Feb 28. 2017
8.55
2 Trading Days
6.14%
Link
LONG
Jun 16. 2017
7.82
Jun 30. 2017
9.12
10 Trading Days
16.58%
Link
LONG
Feb 26. 2018
6.23
Mar 22. 2018
11.79
18 Trading Days
89.33%
Link
LONG
Jan 30. 2019
1.17
Feb 19. 2019
1.29
13 Trading Days
10.58%
Link
Company Information
Stock Symbol
CLSD
Exchange
NasdaqGM
Company URL
http://www.clearsidebio.com
Company Phone
678-270-3631
CEO
Daniel H. White
Headquarters
-
Business Address
900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GEORGIA 30005
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001539029
About

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which develops drug therapies to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and retina. The company was founded by Samirkumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Description

Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.